MENU

Why Pro Medicus Limited (ASX:PME) shares are smoking hot today

Shares in software-as-a-service medical imaging business Pro Medicus Limited (ASX: PME) rocketed more than 10% higher to $7.95 in trade today after the group announced a new deal for its Visage 7 platform with U.S. healthcare group Mercy Health.

The deal is reportedly worth more than $15 million over the next seven years in what Pro Medicus’s ebullient CEO described as “an industry defining deal for us”.

The agreement reportedly means that some 25 million images from Mercy’s current archive can be combined onto the interoperable Visage 7 system in a “totally modular fashion”.

The project is scheduled for completion by early 2019 and its successful implementation will be another big step forward for Pro Medicus in its journey to become a market leader in the online medical imaging platform space.

“Our goal is to be the single enterprise imaging platform for all medical images and multimedia within the healthcare enterprise and this is a very significant step in that direction,” boasted the CEO.

That confidence might not be misplaced as Pro Medicus looks one of the ASX’s best up-and-coming companies as it operates in huge global addressable markets and appears to have a market-leading product that offers the attractive economic characteristics of sticky, recurring revenues, on high gross profit margins.

Pro Medicus’s robust outlook is no secret anymore though, with the company valued at more than $730 million despite posting revenue and profit of just $16.6 million and $5.1 million respectively for the six-month period ending December 31 2017.

Admittedly these are backward looking stats and the group’s high profit margins are a standout feature given it has plenty of new revenue to come online as the result of its new contract wins.

I’d rate the stock a hold for now, but wouldn’t be surprised to see it get a wriggle on into the new financial year.

Others on an arguably even bigger tear in the software-as-service space include Wisetech Global Ltd (ASX: WTC) and Xero Limited (ASX: XRO), both of which are already several multiples the market value size of Pro Medicus.

3 More Revolutionary Aussie Companies to Back for 2018

We’re living in one of the most exciting times in investing history. Innovation and a booming culture of entrepreneurship are constantly creating new companies with the potential to make forward-thinking investors very rich. Now more than ever, one small, smart investment could make a huge difference to your wealth.

That’s why at The Motley Fool we’ve been scrutinizing the ASX to uncover the kinds of companies that we believe could turn into the next Pro Medicus

We’ve found three exciting companies that we believe re poised to perform in the new year. Click here to uncover these ideas!

Motley Fool contributor Tom Richardson owns shares of PRO Medicus Ltd. and Xero.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia owns shares of and has recommended PRO Medicus Ltd. The Motley Fool Australia owns shares of WiseTech Global and Xero. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.